Clinical Trial Update: Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated 5-[123I]-A-85380 with SPECT imaging for Parkinson disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• 5-[123I]-A-85380

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED